Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6IEE7
UPID:
T132E_HUMAN
Alternative names:
-
Alternative UPACC:
Q6IEE7; A0A0J9YW40; Q8WUF4; Q8WVA5
Background:
Transmembrane protein 132E plays a crucial role in hearing, essential for normal inner ear hair cell function. This protein's involvement in the auditory process highlights its significance in maintaining proper sensory input.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 99, a severe form of sensorineural hearing loss, understanding Transmembrane protein 132E's function could pave the way for innovative treatments. Its direct association with this genetic condition underscores the potential for targeted gene therapy.